Current recall status overview
As of the latest official update, Health Canada has issued a recall for specific Dermarite topical skin-care products due to potential microbial contamination and incorrect labeling. This status clarifier explains the products involved, the identified risks, and recommended actions for Canadian consumers and healthcare professionals. The details below are based on publicly available recall notices and regulatory communications.
What prompted the Dermarite recall
The recall was initiated after routine testing detected microorganisms in certain Dermarite containers that could pose infection risks, particularly for individuals with compromised skin barriers or weakened immune systems. In parallel, some units were recalled due to labeling deviations that may affect correct use and safety. The manufacturer coordinated with Health Canada to remove affected lots from distribution and retail while informing prescribers and patients.
Products and lot codes affected
| Product name | Size and form | Lot code(s) | Market region | Primary risk |
|---|---|---|---|---|
| Dermarite Facial Moisturizer | 30 g tube | MFG210425A | National | Microbial contamination |
| Dermarite Healing Ointment | 45 g tube | MFG220110B, MFG220322C | National | Microbial contamination |
| Dermarite Gentle Cleanser | 200 mL bottle | MFG211201D | National | Labeling deviation |
| Dermarite Repair Cream | 35 g tube | MFG220618E | Specific provinces | Labeling deviation |
Health risks and who may be affected
Products with microbial contamination could cause localized infections, folliculitis, or delayed wound healing, especially when used on broken skin or on patients with immunosuppression. Labeling issues could lead to incorrect dosing, unintended ingredient exposure, or misuse in sensitive areas. While no severe adverse events have been widely reported to date, anyone who used affected products and experiences unusual skin symptoms should seek medical advice.
Recommended actions for consumers
- Check lot codes on your Dermarite products against the official recall list.
- Stop using and securely discard any affected units.
- Contact your pharmacist or healthcare provider for guidance on alternative products.
- Return affected items to the place of purchase if instructed or follow disposal guidance.
- Monitor for skin irritation or infection and seek care if symptoms develop.
Role of healthcare providers and pharmacists
Clinicians should confirm whether a patient’s product lot is included in the recall, advise discontinuation if necessary, and recommend suitable alternatives for ongoing skin care. Pharmacists play a key role in verifying lot codes at point of sale and in coordinating with suppliers for replacements or refunds.
Regulatory updates and next steps
Health Canada continues to monitor compliance and may provide further notices if additional lots are identified or if new safety data emerge. The manufacturer is conducting additional stability and sterility testing and is working to resolve the underlying causes before resuming distribution. Stakeholders are encouraged to review official recall notices periodically for any amendments or extensions.